Wedbush added Argenx (ARGX) to the firm’s Best Ideas List as it believes the company is uniquely positioned to deliver sustained, market-leading growth in the autoimmune space, driven by continued expansion of Vyvgart and an emerging pipeline of assets that can sustain long-term momentum. Wedbush has an Outperform rating on the shares with a price target of $715.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx pullback brings ‘attractive buying opportunity,’ says Citi
- Argenx Se: Strong Growth Prospects and Attractive Buying Opportunity Amid Vyvgart Expansion and Upcoming Catalysts
- Argenx price target lowered to $699 from $701 at Citizens JMP
- Argenx upgraded to Outperform from Neutral at Baird
- Argenx Se: Buy Rating Affirmed Amid Pricing Strategy Confidence and Promising Growth Prospects